Next Article in Journal
Aplastic Anemia with Concurrent Temozolomide Treatment in a Patient with Glioblastoma Multiforme
Previous Article in Journal
Radiation Recall Dermatitis with Azithromycin
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 17
Issue 4
10.3747/co.v17i4.519
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Severe Raynaud Syndrome Induced by Adjuvant Interferon Alfa in Metastatic Melanoma

by
H. Husein–ElAhmed
1,*,
J.L. Callejas–Rubio
2,
R. Ortega Del Olmo
3,
R. Ríos–Fernandez
2 and
N. Ortego–Centeno
2
1
Department of Dermatology, San Cecilio University Hospital, Granada, Spain
2
Unit of Systemic Diseases, San Cecilio University Hospital, Granada, Spain
3
Department of Dermatology, School of Medicine, Granada, Spain
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2010, 17(4), 122-123; https://0-doi-org.brum.beds.ac.uk/10.3747/co.v17i4.519
Submission received: 1 July 2010 / Revised: 3 July 2010 / Accepted: 9 July 2010 / Published: 1 August 2010

Abstract

Melanoma is the most lethal form of skin malignancy because of its aggressive behaviour. In advanced disease, interferon alfa can be used as adjuvant therapy. However, this therapy is not free of side effects. We present a case of severe Raynaud syndrome and digital necrosis induced by interferon alfa in a patient with melanoma. Pathogenic mechanisms are discussed.
Keywords: melanoma; treatment; interferon; adjuvant; raynaud syndrome; digital necrosis; vascular toxicity melanoma; treatment; interferon; adjuvant; raynaud syndrome; digital necrosis; vascular toxicity

Share and Cite

MDPI and ACS Style

Husein–ElAhmed, H.; Callejas–Rubio, J.L.; Del Olmo, R.O.; Ríos–Fernandez, R.; Ortego–Centeno, N. Severe Raynaud Syndrome Induced by Adjuvant Interferon Alfa in Metastatic Melanoma. Curr. Oncol. 2010, 17, 122-123. https://0-doi-org.brum.beds.ac.uk/10.3747/co.v17i4.519

AMA Style

Husein–ElAhmed H, Callejas–Rubio JL, Del Olmo RO, Ríos–Fernandez R, Ortego–Centeno N. Severe Raynaud Syndrome Induced by Adjuvant Interferon Alfa in Metastatic Melanoma. Current Oncology. 2010; 17(4):122-123. https://0-doi-org.brum.beds.ac.uk/10.3747/co.v17i4.519

Chicago/Turabian Style

Husein–ElAhmed, H., J.L. Callejas–Rubio, R. Ortega Del Olmo, R. Ríos–Fernandez, and N. Ortego–Centeno. 2010. "Severe Raynaud Syndrome Induced by Adjuvant Interferon Alfa in Metastatic Melanoma" Current Oncology 17, no. 4: 122-123. https://0-doi-org.brum.beds.ac.uk/10.3747/co.v17i4.519

Article Metrics

Back to TopTop